Shanghai Fosun Pharmaceutical (Group) is aiming to bring German partner BioNTech’s coronavirus vaccine to China by the end of the year, pitting it against products made by Chinese and international rivals.“We hope to be able to commercialise it by year end, but there are plenty of uncertainties with clinical trials as well as the regulatory approval processes,” CEO Wu Yifang said in an interview.“Pfizer and BioNTech recently said they are on track to seek regulatory review on the BNT162b2…